Victory Capital Management Inc. Has $588,000 Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Victory Capital Management Inc. grew its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 300.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 68,871 shares of the biopharmaceutical company’s stock after acquiring an additional 51,671 shares during the quarter. Victory Capital Management Inc.’s holdings in Ocular Therapeutix were worth $588,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in OCUL. Palumbo Wealth Management LLC acquired a new position in shares of Ocular Therapeutix during the 4th quarter worth approximately $100,000. China Universal Asset Management Co. Ltd. grew its position in shares of Ocular Therapeutix by 11.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company’s stock worth $285,000 after purchasing an additional 3,347 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Ocular Therapeutix during the 3rd quarter worth approximately $422,000. Truist Financial Corp acquired a new position in shares of Ocular Therapeutix during the 4th quarter worth approximately $427,000. Finally, Courier Capital LLC acquired a new stake in shares of Ocular Therapeutix during the 4th quarter worth approximately $482,000. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix Stock Up 0.9 %

OCUL opened at $7.51 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The company’s 50-day moving average is $7.57 and its 200 day moving average is $8.78. Ocular Therapeutix, Inc. has a fifty-two week low of $4.06 and a fifty-two week high of $11.78. The firm has a market capitalization of $1.19 billion, a P/E ratio of -5.69 and a beta of 1.34.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The company had revenue of $17.08 million during the quarter, compared to the consensus estimate of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. Research analysts expect that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Insider Activity at Ocular Therapeutix

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,475 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the sale, the insider now directly owns 3,520,318 shares in the company, valued at $24,184,584.66. This represents a 0.61 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Donald Notman sold 11,119 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total transaction of $86,839.39. Following the completion of the transaction, the insider now directly owns 193,444 shares in the company, valued at $1,510,797.64. The trade was a 5.44 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 38,895 shares of company stock worth $283,772. 3.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on OCUL. Needham & Company LLC began coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 11th. They set a “buy” rating and a $15.00 price target on the stock. Royal Bank of Canada began coverage on shares of Ocular Therapeutix in a research report on Tuesday. They set an “outperform” rating and a $17.00 price target on the stock. JMP Securities set a $19.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.38.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.